HI-STEM gGmbH is a non-profit public-private partnership between the German Cancer Research Center (DKFZ) in Heidelberg and the Dietmar Hopp Stiftung. HI-STEM performs cutting-edge research on normal and malignant stem cells with the aim of translating these results into novel clinical applications. This includes the development of novel diagnostic tools and innovative therapies to monitor and target leukemic and solid tumor stem cells as well as metastatic disease. HI-STEM was founded in 2008 and is located on the fourth floor of the main building of the DKFZ.
We are an international team of more than sixty scientists, including group leaders, postdoctoral fellows, PhD, MD and MSc. students as well as technical staff. This research team focuses on three major topics and is directed by the managing director of HI-STEM, Professor Dr. Andreas Trumpp, as well as six additional group leaders.
HI-STEM Research Groups:
- Hematopoietic and Leukemic Stem Cells (Andreas Trumpp)
- Junior Group: Stem Cells at the Interface of Hematopoiesis, Immunity and Cancer (Simon Haas)
- Junior Group: Pattern Recognition and Digital Medicine (Daniel Hübschmann)
- Experimental Hematology (Mick Milsom)
- Stress Induced Activation of Hematopoietic Stem Cells (Marieke Essers)
- Metastatic Niches (Thordur Oskarsson)
- Cancer Stem Cells and Metastasis (Martin Sprick and Andreas Trumpp)
Researchers at HI-STEM are working in close collaboration with clinical colleagues of the University Hospitals in Heidelberg and Mannheim as well as with the National Center for Tumor Diseases (NCT) in Heidelberg and members of the German Cancer Consortium (DKTK) as well as international collaborators. In addition, HI-STEM collaborates with various biotechnology and pharmaceutical companies to investigate and develop novel strategies to push forward the development of new drugs and effective treatments for different types of cancer and to promote their clinical application.
Recent Publication Highlights